



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Herzuma

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
N/0066	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	17/10/2024		PL	
II/0061/G	This was an application for a group of variations. B.II.d.2.z - Change in test procedure for the finished	05/09/2024	n/a		

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



<p>product - Other variation</p> <p>B.II.c.3.a.2 - Change in source of an excipient or reagent with TSE risk - From TSE risk material to vegetable or synthetic origin - For excipients or reagents USED in the manufacture of a biol/immunol AS or in a biol/immunol medicinal product</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method</p> <p>B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation</p> <p>B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range</p> <p>B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation</p> <p>B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation</p> <p>B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation</p> <p>B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation</p>				
--	--	--	--	--

	B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.a.2.b - Changes in the manufacturing process of the AS - Substantial change to the manufacturing process of the AS which may have a significant impact on the quality, safety or efficacy of the medicinal product				
IB/0065	B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation	09/08/2024	n/a		
N/0064	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	30/07/2024		PL	
IA/0063/G	This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation A.7 - Administrative change - Deletion of manufacturing sites	20/06/2024	n/a		
IB/0062	B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation	17/04/2024	n/a		

IAIN/0060/G	<p>This was an application for a group of variations.</p> <p>B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing</p> <p>B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing</p> <p>A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)</p>	14/12/2023	16/02/2024	Annex II and PL	
IA/0059	B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation	20/09/2023	n/a		
N/0058	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	19/09/2023	16/02/2024	PL	
IB/0057	B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	26/06/2023	n/a		
IAIN/0056	B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	13/03/2023	n/a		

IAIN/0055	B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	24/01/2023	16/02/2024	Annex II and PL	
IAIN/0054	B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	24/01/2023	16/02/2024	Annex II and PL	
R/0050	Renewal of the marketing authorisation.	15/09/2022	09/12/2022	SmPC, Labelling and PL	Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Herzuma in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.
N/0053	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	30/09/2022	16/02/2024	PL	
IA/0052/G	This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure B.II.e.1.b.3 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Deletion of an immediate packaging	15/07/2022	n/a		

	<p>container without a complete deletion of a strength or pharmaceutical form</p> <p>B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State</p>				
PSUSA/3010/202109	Periodic Safety Update EU Single assessment - trastuzumab	10/06/2022	n/a		PRAC Recommendation - maintenance
IA/0051	B.I.c.z - Container closure system of the AS - Other variation	24/05/2022	n/a		
N/0049	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	06/04/2022	09/12/2022	PL	
II/0038	B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method	03/02/2022	n/a		
IA/0048	A.6 - Administrative change - Change in ATC Code/ATC Vet Code	31/01/2022	09/12/2022	SmPC	
IB/0046/G	<p>This was an application for a group of variations.</p> <p>B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation</p> <p>B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation</p>	25/01/2022	n/a		

II/0041/G	<p>This was an application for a group of variations.</p> <p>B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation</p> <p>B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol</p> <p>B.I.b.1.e - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a specification parameter which may have a significant effect on the overall quality of the AS and/or the FP</p>	09/12/2021	n/a		
IA/0045	B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method	06/12/2021	n/a		
IB/0044	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	16/11/2021	16/12/2021	SmPC, Annex II and PL	
N/0043	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	29/09/2021	16/12/2021	PL	

IB/0042	B.II.d.1.d - Change in the specification parameters and/or limits of the finished product - Deletion of a non-significant specification parameter	03/09/2021	n/a		
IB/0040	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	26/07/2021	16/12/2021	SmPC and PL	
IA/0039/G	<p>This was an application for a group of variations.</p> <p>B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits</p> <p>B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits</p> <p>B.I.c.2.b - Change in the specification parameters and/or limits of the immediate packaging of the AS - Addition of a new specification parameter to the specification with its corresponding test method</p> <p>B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method</p>	26/04/2021	n/a		
II/0035/G	This was an application for a group of variations.	25/03/2021	n/a		

	<p>A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient</p> <p>B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes</p> <p>B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method</p> <p>B.II.e.1.b.2 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Sterile medicinal products and biological/immunological medicinal products</p>				
IA/0037	A.7 - Administrative change - Deletion of manufacturing sites	10/02/2021	16/12/2021	Annex II and PL	
IB/0036	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	15/01/2021	16/12/2021	SmPC and PL	

II/0032/G	<p>This was an application for a group of variations.</p> <p>B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation</p> <p>B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol</p> <p>B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation</p>	10/12/2020	n/a		
II/0031	B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method	22/10/2020	n/a		
N/0033	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	30/09/2020	16/12/2021	PL	
IB/0034	B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation	08/09/2020	n/a		
IB/0030	B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time	26/06/2020	n/a		

	data				
N/0029	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	20/05/2020	15/09/2020	PL	
IB/0028	B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol	03/04/2020	15/09/2020	SmPC	
IB/0027/G	<p>This was an application for a group of variations.</p> <p>B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data</p> <p>B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p>	27/03/2020	n/a		
IB/0026/G	<p>This was an application for a group of variations.</p> <p>B.II.b.4.f - Change in the batch size (including batch size ranges) of the finished product - The scale for a biological/immunological medicinal product is increased/decreased without process change (e.g. duplication of line)</p>	19/03/2020	n/a		

	B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation				
IB/0025/G	<p>This was an application for a group of variations.</p> <p>B.II.f.1.b.3 - Stability of FP - Extension of the shelf life of the finished product - After dilution or reconstitution (supported by real time data)</p> <p>B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol</p> <p>B.II.f.1.e - Stability of FP - Change to an approved stability protocol</p>	21/01/2020	15/09/2020	SmPC and PL	
IA/0024/G	<p>This was an application for a group of variations.</p> <p>B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits</p> <p>B.I.c.2.a - Change in the specification parameters and/or limits of the immediate packaging of the AS - Tightening of specification limits</p> <p>B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process</p> <p>B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process</p> <p>B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished</p>	15/11/2019	n/a		

	product - Addition of a new test(s) and limits B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits				
II/0023	C.I.13: Submission of the final report of study CT-P6 3.2; this is a phase 3, double blind, randomized, parallel-group, active-controlled study to compare the efficacy and safety of CT-P6 and Herceptin as Neoadjuvant and Adjuvant treatment in patients with HER2 positive early breast cancer. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority	10/10/2019	n/a		
PSUSA/3010/201809	Periodic Safety Update EU Single assessment - trastuzumab	29/05/2019	01/08/2019	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/3010/201809.
IB/0021	C.I.2.z - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Other variation	10/07/2019	15/09/2020	SmPC and PL	
IB/0022/G	This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other	03/07/2019	n/a		

	<p>variation</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p>				
IAIN/0020	<p>B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing</p>	12/04/2019	n/a		
II/0012	<p>B.II.b.1.d - Replacement or addition of a manufacturing site for the FP - Site which requires an initial or product specific inspection</p>	28/03/2019	n/a		
IA/0019/G	<p>This was an application for a group of variations.</p> <p>B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits</p> <p>B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits</p> <p>B.I.b.1.c - Change in the specification parameters</p>	21/03/2019	n/a		

<p>and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method</p> <p>B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method</p> <p>B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits</p> <p>B.II.c.1.a - Change in the specification parameters and/or limits of an excipient - Tightening of specification limits</p> <p>B.II.e.3.a - Change in test procedure for the immediate packaging of the finished product - Minor changes to an approved test procedure</p> <p>B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State</p> <p>B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State</p> <p>B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a</p>				
---	--	--	--	--

	Member State				
IB/0018	B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol	07/03/2019	01/08/2019	SmPC and PL	
IG/1053/G	<p>This was an application for a group of variations.</p> <p>B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing</p> <p>B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing</p>	28/01/2019	01/03/2019	Annex II and PL	
IB/0015/G	<p>This was an application for a group of variations.</p> <p>B.II.f.1.b.3 - Stability of FP - Extension of the shelf life of the finished product - After dilution or reconstitution (supported by real time data)</p> <p>B.II.f.1.e - Stability of FP - Change to an approved stability protocol</p>	14/01/2019	01/03/2019	SmPC and PL	
IB/0014	B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol	12/11/2018	01/03/2019	SmPC and PL	

IAIN/0013	B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	26/10/2018	n/a		
II/0006	B.II.e.5.c - Change in pack size of the finished product - Change in the fill weight/fill volume of sterile multidose (or single-dose, partial use) parenteral medicinal products, including biological/immunological medicinal products	20/09/2018	01/03/2019	SmPC, Annex II, Labelling and PL	
II/0005	B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes	13/09/2018	n/a		
IB/0011/G	<p>This was an application for a group of variations.</p> <p>C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH</p> <p>C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by</p>	23/08/2018	01/03/2019	SmPC and PL	

	the MAH				
IB/0009/G	<p>This was an application for a group of variations.</p> <p>B.II.b.4.f - Change in the batch size (including batch size ranges) of the finished product - The scale for a biological/immunological medicinal product is increased/decreased without process change (e.g. duplication of line)</p> <p>B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation</p>	17/08/2018	n/a		
IB/0008	B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data	19/07/2018	n/a		
IAIN/0007	B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	11/06/2018	n/a		
IAIN/0004	B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	30/04/2018	n/a		
IB/0003/G	<p>This was an application for a group of variations.</p> <p>B.II.b.4.f - Change in the batch size (including batch size ranges) of the finished product - The scale for a biological/immunological medicinal product is increased/decreased without process change (e.g.</p>	27/03/2018	n/a		

	<p>duplication of line)</p> <p>B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits</p> <p>B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits</p> <p>B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation</p> <p>B.II.e.1.z - Change in immediate packaging of the finished product - Other variation</p> <p>B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information</p>				
IB/0002	B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol	15/03/2018	01/03/2019	SmPC	
IAIN/0001	A.1 - Administrative change - Change in the name and/or address of the MAH	12/03/2018	01/03/2019	SmPC, Labelling and PL	